FOXO4-DRI Price: $67 a Vial and a Moving Per-mg Figure

Summary: The headline price is simple, but the per-milligram figure everyone quotes depends on an assumption the vendor's own laboratory reports contradict.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The FOXO4-DRI price is $67.00 for a 10 mg vial once the discount code is applied, down from a $134.00 current price and a $199.99 list. That part is simple. Dividing by ten to reach a cost per milligram is where it stops being simple, because the vendor's own certificates disagree about how much peptide the vial contains.

What the vial costs

Unlike most peptides in this market, FOXO4-DRI comes in a single 10 mg presentation. That removes the usual optimisation, where a larger vial carries a better per-milligram rate and the buying decision becomes partly arithmetic. Here there is one product, and quantity is the only lever.

Buying multiples reduces the per-unit price: three at $129.98 each, five at $127.30, ten at $120.60, coming to $389.94, $636.50 and $1,206.00. Those are reductions against the current price rather than the discounted price, and whether a bulk tier and the code combine is worth confirming in the cart rather than assuming.

The per-milligram figure is softer than it looks

Two laboratories have certified this product on two different batches. Kovera Labs certified batch 55-05260628 in June 2026 at 99.411% purity with net content of 11.41 mg. MZ Biolabs analysed lot 55-01260229 in January 2026 at 99.97% purity with net content of 8.30 mg. Both vials were labelled 10 mg.

A spread of roughly 37% on the figure most pages quote as a single confident number. It runs in the buyer's favour on one batch and against them on the other, which is worth saying plainly rather than framing entirely as a warning.

Neither certificate is defective. Purity and net content are separate measurements, and both purity results were excellent. What moved is quantity, which is the measurement almost nobody in this market publishes at all.

The practical conclusion: cost per milligram is a weak comparison metric for this compound. If per-mg matters to your comparison, use the figure from the certificate for your lot, not the label.

Why insurance never enters into it

A cost article for an approved medicine would weigh copay against cash price, discuss manufacturer savings cards and compare telehealth bundles. None of that framework applies.

FOXO4-DRI has no marketing authorisation from the FDA, the EMA or the MHRA ^[1]. No approved product means no formulary listing, no negotiated rate, no savings programme and nothing for an insurer to reimburse. It has also never been given to a human in a registered trial, so the evidence that normally precedes any of those arrangements does not exist.

That leaves research-supply pricing as the only pricing there is, set by suppliers competing on cost and, if you are fortunate, on documentation.

What the price is actually buying

Since the number itself is settled, the more useful question is what $67.00 obtains that a cheaper listing would not.

It buys documentation, and specifically documentation you can tie to your own vial. Two named laboratories with real addresses have tested this product, using both purity and identity methods rather than purity alone, and one of the two batches carries endotoxin and sterility screening as well. Measured net content is published rather than assumed, which is the disclosure this article has spent most of its length on precisely because it is so rare.

It does not buy a guarantee of consistency. The two published batches differed by 37% in delivered peptide, and the contamination screening exists on one of them and not the other. Both of those facts are knowable only because the vendor published enough for them to be knowable, which is an odd kind of reassurance but a real one.

What no price in this market buys is regulatory oversight. There is no inspector, no approved manufacturing standard for this compound, and no authority checking the claims on any listing. Paying more does not purchase that, and any vendor implying otherwise is selling something they do not have.

Comparing against the wider peptide market

Readers arriving from other compounds usually want to know whether $6.70 per milligram is expensive, and the honest answer is that the comparison does not transfer well.

Peptides vary enormously in synthesis difficulty, and price tracks that more than it tracks anything else. FOXO4-DRI is a long, complex molecule at 228 carbons, built entirely from D-amino acids in reversed sequence, which is a more demanding synthesis than an ordinary short peptide. Comparing its per-milligram cost against a small, simple, widely produced compound is comparing manufacturing difficulty, not value.

The comparison that does transfer is documentation per dollar. Across any compound, the question worth asking is whether the supplier publishes a batch-specific certificate from a named laboratory, whether it runs identity as well as purity, and whether it states measured content. That standard is portable, and it is the one the BPC-157 price breakdown applies to a compound at a very different price point.

Judging whether a price is plausible

Without a reference price to anchor against, the useful test is not whether a price is low but whether the documentation justifies it.

A vial well below the market, sold with no lot number, no named laboratory and no measured content figure, is not a bargain. The cost of discovering it was not what the label said is unrecoverable, and there is no analytical service most buyers can practically use.

A higher price does not buy quality by itself either. What justifies a price here is a batch-specific certificate from a named laboratory, running purity and identity methods, ideally with contamination screening, stating measured content rather than repeating the label. Ascension does the first four. Contamination screening exists on one of the two published batches and not the other, which is again a batch property rather than a product guarantee.

For the arithmetic that follows from whichever figure applies to your vial, the peptide calculator handles it, and the same label-versus-measured question is worked through for NAD where the quantities make the discrepancy easier to see.

How much does FOXO4-DRI cost?

A 10 mg vial lists at $199.99, currently sells at $134.00, and comes to $67.00 with the code PEPTIDEDECK. That is $6.70 per mg against the labelled mass. Free shipping begins at $250.

Why does the cost per milligram vary?

Because measured net content varies between batches. The two published certificates recorded 11.41 mg and 8.30 mg in vials labelled 10 mg, putting the effective cost at roughly $5.87 or $8.07 per mg. The price does not change; the amount of peptide does.

Is there a cheaper larger vial?

No. FOXO4-DRI is sold only in a 10 mg format, so the per-milligram saving that usually comes with a larger vial is unavailable. Quantity discounts of 3%, 5% and 10% apply at three, five and ten units.

Will insurance cover it?

No. There is no approved FOXO4-DRI product in any market, so there is no indication to cover, no formulary placement and no reimbursement pathway.